ArticleVaccines2025
Adverse Events Following
Article in Vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Surveillance and analysis of adverse events following immunization (AEFI) with measles, mumps, and rubella (MMR) vaccine in Zhejiang Province, China, 2020-2025.Frontiers in public health · 2026Article
- Parents' preference for the inclusion of pediatric vaccines in the Chinese National Immunization Program: A discrete choice experiment.Human vaccines & immunotherapeutics · 2025Article
- Reporting profile of adverse events following DTaP-IPV/Hib pentavalent vaccine: A 13-year real-world surveillance data analysis.Human vaccines & immunotherapeutics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe
methodsHib vaccine-related AEFIs in Zhejiang Province from 1 January 2017, to 31 December 2023, were collected through the Chinese National AEFI Information System (CNAEFIS) for a descriptive epidemiological analysis.
resultsFrom 2017 to 2023, a total of 1740 Hib vaccine-related AEFIs were reported (incidence rate: 63.01/100,000 doses) (95%CI: 60.12/100,000 doses-66.04/100,000 doses), including 1577 common adverse reactions (57.10/100,000 doses) (95%CI: 54.35/100,000 doses-59.99/100,000 doses), 139 rare adverse reactions (5.03/100,000 doses) (95%CI: 4.26/100,000 doses-5.94/100,000 doses), and 24 coincidental events (0.87/100,000 doses) (95%CI: 0.58/100,000 doses-1.29/100,000 doses). Most of the AEFIs were common adverse reactions that manifested mainly as fever, injection site redness and swelling, and crying. AEFIs were more likely to occur in male participants under the age of one, in summer and autumn, and during the booster immunity stage. The top three regions with the highest reported incidence rates of AEFIs were Jiaxing City (86.61/100,000 doses) (95%CI: 74.44/100,000 doses-100.77/100,000 doses), Hangzhou City (81.29/100,000 doses) (95%CI: 72.56/100,000 doses-91.07/100,000 doses), and Taizhou City (66.62/100,000 doses) (95%CI: 58.24/100,000 doses-76.21/100,000 doses).
conclusionsOur findings provide preliminary evidence of the safety profile of the Hib vaccine at a provincial level, which adds further support for its broader implementation in other provinces. Future multi-center studies are needed to construct a comprehensive vaccine evaluation framework and make multi-criteria decisions on the feasibility of incorporating the Hib vaccine into China's NIP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.